Drug compounding was meant for individual patients
Wish I had started sooner
1 Its been studied that semaglutide primarily mimics the effects of GLP-1 released from the gut, not the brain

Tirzepatide Once Weekly for the Treatment of Obesity (June 4, 2022) MOUNJARO (tirzepatide) Injection, for subcutaneous use (2022) Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (May 11, 2025) Tirzepatide Once Weekly For The Treatment Of Obesity In People With Type 2 Diabetes (Surmount-2): A Double-Blind, Randomised, Multicentre, Placebo-Controlled, Phase 3 Trial (August 19, 2023) Efficacy And Safety Of A Novel Dual GIP And GLP-1 Receptor Agonist Tirzepatide In Patients With Type 2 Diabetes (Surpass-1): A Double-Blind, Randomised, Phase 3 Trial (July 10, 2021) Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (June 25, 2021) Zepbound (tirzepatide) Injection, for subcutaneous use (2022) The Risk Of Depression, Anxiety, And Suicidal Behavior In Patients With Obesity On Glucagon Like Peptide-1 Receptor Agonist Therapy (October 18, 2024)
"Update: I looked into my symptoms and some of it could be due to anaemia